XML 30 R8.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Share-Based Compensation | 6 Months Ended
--- | ---
Dec. 31, 2014
Share-Based Compensation |
(3) | Share-Based Compensation
The Company maintains a share-based compensation plan, the 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2010 Plan”), that has been approved by the Company’s shareholders. The 2010 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors. On December 5, 2013, the shareholders approved an amendment to the 2010 Plan to set the number of shares available for grant to 3,500,000. At December 31, 2014, 1,809,802 shares were available for issuance. In addition, as of December 31, 2014, the Company may grant up to 4,496,736 additional shares under the 2010 Plan if options previously granted under the Company’s terminated 2003 Employee, Director and Consultant Option Plan are cancelled or expire without the issuance of shares of common stock by the Company. The number of shares, terms, and vesting period of awards under the 2010 Plan are determined by the Compensation Committee of the Board of Directors for each equity award. Stock options granted under the plan prior to December 5, 2012 generally vest ratably over four years and expire ten years from the grant date. Stock options granted after December 5, 2012 generally vest ratably over four years and expire eight years from the grant date. The exercise price of options granted is equivalent to the fair market value of the stock on the grant date. In September 2014, the Company began issuing restricted stock units (“RSUs”) which vest ratably over four years on the anniversary date of the grant in lieu of stock options to all employees and directors. The number of RSUs awarded to certain executive officers may be reduced if certain additional functional performance metrics are not met. Stock Options A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2014 is as follows:
|  | Number of shares |  |  | Weighted average exercise price |
Options outstanding at June 30, 2014 |  |  | 14,238,603 |  |  | $ | 23.30 |
Options granted |  |  | 1,000 |  |  |  | 37.17 |
Less: |  |  |  |  |  |  |  |
Options exercised |  |  | 873,774 |  |  |  | 19.91 |
Options canceled or expired |  |  | 254,087 |  |  |  | 25.75 |
Options outstanding at December 31, 2014 |  |  | 13,111,742 |  |  | $ | 23.48 |
As of December 31, 2014, options to purchase 8,803,382 shares were vested and exercisable at a weighted average price of $22.64. As of December 31, 2014, there was $28.7 million of total unrecognized share-based compensation expense related to stock options that will be recognized over a weighted-average period of 1.92 years. Restricted Stock Units A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2014 is as follows:
|  | Number of shares |  |  | Weighted average grant date fair value |
RSUs outstanding at June 30, 2014 |  |  | — |  |  | $ | — |
RSUs granted |  |  | 1,179,633 |  |  |  | 37.85 |
Less: |  |  |  |  |  |  |  |
RSUs vested |  |  | — |  |  |  | — |
RSUs canceled |  |  | 79,450 |  |  |  | 38.12 |
RSUs outstanding at December 31, 2014 |  |  | 1,100,183 |  |  | $ | 37.84 |
The grant date fair value of an RSU equals the closing price of our common stock on the grant date. The weighted average grant date fair value for the six months ended December 31, 2014 is $37.85. As of December 31, 2014, no RSUs were vested. As of December 31, 2014, there was $31.3 million of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.98 years. This unrecognized compensation expense is equal to the fair value of RSUs expected to vest. Employee Stock Purchase Plan The Company also has an Employee Stock Purchase Plan that was approved by shareholders in 2012 (the “2012 Purchase Plan”), under which 2,000,000 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. As of December 31, 2014, approximately 334,000 shares of common stock have been issued under the 2012 Purchase Plan and approximately 1,666,000 were available for issuance. Share-Based Compensation Expense Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:
|  | Three months ended |  |  | Six months ended |
|  | December 31, |  |  | December 31, |
(In thousands) |  | 2014 |  |  | 2013 |  |  | 2014 |  |  | 2013 |
Cost of molecular diagnostic testing |  | $ | 249 |  |  | $ | 209 |  |  | $ | 447 |  |  | $ | 432 |
Cost of pharmaceutical and clinical services |  |  | 123 |  |  |  | 74 |  |  |  | 283 |  |  |  | 137 |
Research and development expense |  |  | 1,252 |  |  |  | 846 |  |  |  | 2,017 |  |  |  | 1,627 |
Selling, general, and administrative expense |  |  | 10,523 |  |  |  | 5,728 |  |  |  | 16,281 |  |  |  | 11,596 |
Total share-based compensation expense |  | $ | 12,147 |  |  | $ | 6,857 |  |  | $ | 19,028 |  |  | $ | 13,792 |
In October 2014 the Company and its former Chief Financial Officer entered into a resignation agreement under which the vesting of certain awards were modified such that the specified awards were vested in full. As a result of this award modification the company recognized approximately $3.1 million in share-based compensation expense for the three and six months ending December 31, 2014.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration